INS and type 2 diabetes mellitus: In conclusion, imeglimin directly enhances insulin secretion from β-cells, increases the number of insulin granules, exerts beneficial effects on morphology in β-cell mitochondria, and reduces β-cell apoptosis in type 2 diabetic mice, which finally leads to enhancement of glucose-stimulated insulin secretion and amelioration of glycemic control.